News

Public · Published

Oruka's Psoriasis Treatment Could Generate $7B In Peak Sales, Says Guggenheim – ORKA Stock Heads For Best Day In Over 4 Months

Oruka Therapeutics said its Phase 2b trial of an experimental psoriasis treatment showed about 61% of patients on the highest 600 mg dose had completely clear symptoms after week 16, versus none on placebo. Guggenheim reaffirmed its bullish view, and the stock rose over 13%.

Published:

Updated:

What happened

Oruka Therapeutics said its Phase 2b trial of an experimental psoriasis treatment showed about 61% of patients on the highest 600 mg dose had completely clear symptoms after week 16, versus none on placebo. Guggenheim reaffirmed its bullish view, and the stock rose over 13%.

Confirmed

Global impact / market context

Strong trial results and a supportive analyst view can raise expectations that the treatment will reach the market and sell well. Guggenheim's $7 billion peak sales estimate, which means projected yearly revenue at its height, suggests investors see a large commercial opportunity.

Analyst inference

The stock jumped over 13%, broke above its 50-day moving average, which means a common trend line tracked by traders, and headed for its best day since June. That suggests investors were repositioning toward the shares after the data.

Analyst inference

What to watch

  1. Oruka plans to engage with regulatory agencies and start Phase 3 trials of ORKA-001 in the first half of next year, a later and larger stage of testing needed before approval. Confirmed
  2. Guggenheim's $7 billion peak sales projection is an analyst estimate, not a company forecast, so watch whether future trial data and eventual pricing support that figure. Proposed
  3. Watch whether the trial's strong symptom-clearing results hold in larger Phase 3 testing, since a smaller mid-stage study can overstate how well a treatment performs. Analyst inference

Evidence